KANABO Research Ltd, a wholly owned subsidiary of Kanabo Group Plc, known for research and development, and technology design, today announced a partnership with leading biotechnology research company Pomicell Ltd.
The partnership provides exclusivity in Kanabo’s primary markets for cannabis products and allows Kanabo’s medical cannabis and consumer wellbeing CBD formulas to be submitted to Pomicell’s multi-disciplinary team of biologists and research experts for analysis using its ground-breaking POMI AI platform.
This announcement represents the first time this technology will be applied to medicinal cannabis and wellbeing CBD formulas, having previously been utilised primarily for traditional pharmaceutical products.
Pomicell’s deep-learning AI technology will cross reference the active ingredients within each formula against more than 40 million clinical data and scientific research resources to identify specific indication-target associations.
The partnership’s findings will highlight potential areas for Kanabo to lead the way in creating new products for specific indications via Pomicell’s online platform. Kanabo customers will be able to review ingredients within formulas and identify which are best suited to their specific medical, wellness, or lifestyle needs
Avihu Tamir, CEO Kanabo Group Plc, explains: “For the first time, we will provide our customers with a resource that transparently supplies them with information about what the product is optimized for.
“Secondly, it’s a step closer to providing personalised Kanabo solutions for our customers. With this analysis, we will develop formulas with the active ingredients to suit specific indications for medical and wellness needs.
“Ultimately, this partnership is a further commitment by Kanabo Group to invest in science-based evidence for its products to continuously improve the way we develop them, support our customers, and create products that are effective to the consumer and patients’ needs.
Boaz Buchandler, CEO of Pomicell Ltd, said: “The opportunity this new partnership offers with Kanabo to improve the way customers and patients engage with CBD and medicinal cannabis products is truly exciting.
“With our technology and expertise, we will break Kanabo formulations down to their active ingredient levels and then cross reference each one against more than 40 million clinical trial and scientific data resources.
“Our POMI AI system can do this in minutes, connecting each active ingredient with known and proven indication and effects benefits.
“Not only will Kanabo customers, for the first time, be able to identify formulations best suited to their individual needs, but this detailed analysis will provide the foundations for Kanabo to change the way CBD and medical cannabis formulas are created.
“Kanabo are the perfect partner to lead this new direction with us, and we’re looking forward to giving patients and customers more control over their CBD and medical cannabis choices than ever before.”
